Cargando…

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib (RUX), an oral JAK1 and JAK2 inhibitor, has recently been approved for patients with SR-aGVHD. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Koclęga, Anna, Woźniczka, Krzysztof, Węglarz, Patryk, Boral, Kinga, Kata, Dariusz, Zielińska, Patrycja, Helbig, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668796/ https://www.ncbi.nlm.nih.gov/pubmed/35972605 http://dx.doi.org/10.1007/s12185-022-03434-5

Ejemplares similares

Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
por: Duda, Katarzyna, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience
por: Duda, Katarzyna, et al.
Publicado: (2023)

Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center
por: Kopińska, A., et al.
Publicado: (2021)

Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
por: Spałek, Adrianna, et al.
Publicado: (2022)

Double Malignancy and Double Transplant—A Bumpy Road to Success
por: Razik, Michał, et al.
Publicado: (2023)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

P1349: EFFECT OF TRANSPLANTED CD184-POSITIVE CELLS (WITH EXPRESSION CXCR4) FOR A LONG SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA – ONE CENTER PROSPECTIVE STUDY.
por: Kopinska, A., et al.
Publicado: (2022)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
por: Jaramillo, Sonia, et al.
Publicado: (2020)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

P1535: ASSESSMENT OF COLONIZATION AND INFECTION EPIDEMIOLOGY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A PROSPECTIVE MULTI-CENTER STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG).
por: Pluta, Agnieszka, et al.
Publicado: (2023)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

The kinetics of mRNA transforming growth factor beta1 expression and its serum concentration in graft-versus-host disease after allogeneic hemopoietic stem cell transplantation for myeloid leukemias
por: Kyrcz-Krzemień, Sławomira, et al.
Publicado: (2011)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies
por: Zhang, Meng-yun, et al.
Publicado: (2022)

Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström’s Macroglobulinemia
por: Kopińska, Anna J., et al.
Publicado: (2017)

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
por: D’Alessio, A., et al.
Publicado: (2020)

Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera
por: Swei, Eric C., et al.
Publicado: (2022)

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease
por: Levy, Ofer, et al.
Publicado: (2022)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
por: Tomomasa, Dan, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
por: SOYER, Nur, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rket2ln25uio41kngpjj2ig9vv